Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Its U.S. products are VOQUEZNA tablets, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, all containing vonoprazan, an oral potassium-competitive… From the company’s description.
Over the twelve months to Sep 30, 2026, Phathom Pharmaceuticals, Inc. reported revenue of $274.88M, up 86.8% from a year earlier, and a net loss of $83.00M. Its operating margin was −9.3%, and operations used $20.74M in cash. In fiscal 2025, it reported revenue of $175.11M, up 216.9% from fiscal 2024, and a net loss of $221.25M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Phathom Pharmaceuticals, Inc. does
In the company’s own words
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Its U.S. products are VOQUEZNA tablets, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, all containing vonoprazan, an oral potassium-competitive acid blocker. VOQUEZNA is approved for adults with erosive and non-erosive gastroesophageal reflux disease (GERD) and, with antibiotics, for Helicobacter pylori infection; the co-packaged DUAL PAK and TRIPLE PAK are approved for H. pylori infection. The company sells its products in the United States through wholesale distributors and select pharmacies, serving patients through healthcare providers, including gastroenterologists and primary care physicians. It independently commercializes the products with a targeted sales force and reports one business focus rather than separate reportable segments. As of February 13, 2026, more than 1.1 million prescriptions had been filled since launch, and VOQUEZNA had access for more than 120 million commercially insured U.S. lives. Phathom licensed vonoprazan rights for the United States, Europe and Canada from Takeda in 2019. Its website is www.phathompharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FLORHAM PARK, NJ
- Fiscal year end
- December
- CIK
- 1783183
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Phathom Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Phathom Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Phathom Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Phathom Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Phathom Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”